Breaking News

CSL Licenses Selexis Cell Line

CSL to use SUREtechnology for antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CSL Ltd. has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody for Phase I clinical trials. Under the agreement, CSL has rights to use a cell line generated using the Selexis SUREtechnology Platform for the cGMP production of an undisclosed antibody. “We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform,” said Dr. Igor Fisch, chief executive officer, Selexis SA. &#8220...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters